magyarcég
Egészségügy
Pharmahungary Group

Pharmahungary Group

Provider of preclinical and clinical R&D services for pharmaceutical and medical device development.

  • Provision of preclinical R&D services
  • Provision of clinical R&D services
  • Strategic regulatory and scientific consultancy for drug and medical device development
  • Management of Investigator Initiated Trials and niche clinical trials
  • Development and valorization of in-house R&D projects and bioinformatics tools

Bemutatkozás

Pharmahungary Group is an R&D company with over 20 years of experience and more than 300 development projects. It offers comprehensive preclinical R&D services, including cardiovascular, metabolic, renal, inflammation, and neuropathy disease models, large animal studies, and specialized testing. The company also provides clinical R&D services for medical devices, in vitro diagnostics, combination products, and drugs, encompassing full CRO support, regulatory, and ethics committee management. Additionally, Pharmahungary Group develops novel in-house R&D projects for diagnostics and therapeutics, which are available for out-licensing, co-development, and investment.

Szolgáltatások, tevékenységek

  • Preclinical R&D services for cardiovascular diseases
  • Preclinical R&D services for metabolic diseases
  • Preclinical R&D services for renal diseases
  • Preclinical R&D services for inflammation diseases
  • Preclinical R&D services for neuropathy diseases
  • Provision of large animal models (porcine, Göttingen minipig)
  • Conducting multicenter preclinical proof-of-concept studies
  • Provision of cardiac electrophysiology models (voltage clamp, microelectrode technique)
  • Matrix Metalloproteinase Inhibitor Screening
  • Testing cardioprotective compounds on acute and chronic coronary occlusion-induced myocardial ischemia/reperfusion
  • Testing cardioprotective compounds on myocardial infarction
  • Testing cardioprotective compounds on preconditioning and postconditioning
  • Testing compounds for heart failure induced by chronic coronary occlusion-induced infarction
  • Testing compounds for heart failure induced by cardiotoxic agents
  • Testing cardioprotective compounds in organ storage models
  • Testing vascular functions in hyperlipidemia/atherosclerosis models
  • Testing vascular functions in nitrate-tolerance models
  • Evaluation of antidiabetic compounds in type 1 diabetic models (STZ, Goto-Kakizaki, Zucker Diabetic Fatty)
  • Evaluation of antidiabetic compounds in type 2 diabetic models (STZ, Goto-Kakizaki, Zucker Diabetic Fatty)
  • Evaluation of compounds acting on the nitric oxide-cGMP system
  • Evaluation of compounds acting on peroxynitrite formation
  • Testing antiplatelet compounds in platelet aggregation systems
  • Testing antioxidant agents in cardiovascular disease models
  • Testing antioxidant agents in metabolic disease models
  • Evaluation of cardiac heat-shock protein (HSP) inducers
  • Evaluation of matrix metalloproteinase (MMP) inhibitors
  • Clinical R&D services for medical devices
  • Clinical R&D services for In Vitro Diagnostics
  • Clinical R&D services for combination products
  • Clinical R&D services for drugs (small molecules, biologics, ATMPs)
  • Management of Investigator Initiated Trials (IITs)
  • Management of niche clinical trials
  • Scientific consultancy for preclinical and clinical development
  • Medical writing services
  • Strategic regulatory consultancy
  • Strategic ethics committee consultancy
  • Planning clinical trials
  • Organizing clinical trials
  • Managing clinical trials
  • Conducting feasibility studies for clinical trials
  • National Competent Authority submission for clinical trials
  • Ethics Committee submission for clinical trials
  • Monitoring clinical trials
  • Site management for clinical trials
  • Contract management for clinical trials
  • Training on medical device development
  • Training on medical device regulation
  • Training on EU standards for medical devices
  • Development of novel in-house R&D projects for diagnostics
  • Development of novel in-house R&D projects for therapeutics
  • Out-licensing of R&D projects
  • Co-development of R&D projects
  • Seeking investment for R&D projects
  • Development of ProtectomiR (cytoprotective miRNA targets)
  • Development of Infarnosys (biomarker diagnostic system for acute myocardial ischemia/reperfusion injury)
  • Development of Vezics (modular and scalable chromatography platform for exosome isolation)
  • Development of miRNAtarget (bioinformatics project for target prediction)
  • Development of Vigilace (bioinformatics project for prediction and determination of adverse events and drug interactions)
  • Development of InfarctSizeAI (AI-assisted analysis of infarct regions and sizes on animal heart images)

Cím és elérhetőség

Pharmahungary Group OfficeSzékhely

1031 Budapest, 7 Záhony street, Graphisoft Park

Cégadatok

Cégnév
PHARMAHUNGARY 2000 Kft.
Székhely
Hajnoczy str. 6., Szeged H-6722, Hungary
Adószám
13109202-2-06
Cégjegyzékszám
Cg. 06-09-008744
Postacím / telephely
Graphisoft Park, Building I, Zahony str. 7., Budapest H-1031, Hungary

A cégadatok a vállalkozás saját weboldalán közzétett impresszumból származnak.

Hasonló cégek – Budapest

További cégek – Budapest

Összes cég – Budapest